How do in vitro diagnostic reagent companies build high-throughput screening product lines?

Define screening indicators based on intended use

Before developing high-throughput screening reagents, companies should first clarify the target sample type, applicable population, and screening scenario. For example, blood nucleic acid screening has high requirements for sensitivity and contamination prevention, while autoantibody profile screening focuses more on the discrimination of multiplex parallel detection. A clear definition of the intended use helps with subsequent raw material selection, reaction system optimization, and performance evaluation scheme design, avoiding confusion between the functional boundaries of screening reagents and confirmatory reagents.

Design of key raw materials and reagent components

High-throughput screening reagents usually involve multi-component reaction systems, including solid-phase carriers, labels, buffers, and stabilizers. When selecting raw materials, batch-to-batch consistency and supply stability need to be considered, such as the coating uniformity of microplates, the particle size distribution of magnetic beads, and the retention of enzyme-labeled conjugate activity. Kits are often provided in pre-dispensed or lyophilized form to simplify operation, but compatibility with different instrument models needs to be verified in advance.

Automation compatibility and consumable matching

High-throughput screening cannot be separated from automated equipment. The degree of matching between the kit and liquid handling workstations, plate washers, and readers directly affects operational efficiency. During product development, companies should test with deep-well plates, pipette tips, and sealing films of common specifications to evaluate pipetting precision, residual volume, and evaporation control. For different throughput needs, breakable plate strips or full-plate packaging can be provided to improve flexibility of use.

Performance evaluation and stability observation

Before a reagent is launched, basic studies such as limit of detection, precision, cross-reactivity, and interference tests generally need to be completed, and methodological comparison should be conducted in combination with real clinical samples. In terms of stability, it is necessary to observe the effects of in-use period after opening, transport temperature fluctuations, and repeated freeze-thaw cycles on reagent performance. All performance data are only for internal quality assessment and should not be publicly promoted as absolute standards.